期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

晚期滤泡性淋巴瘤的个体化治疗策略 被引量：3

原文传递
导出
摘要 滤泡性淋巴瘤（follicular lymphoma,FL）是非霍奇金淋巴瘤（non-Hodgkin’s lymphoma,NHL）中仅次于弥漫大B细胞淋巴瘤（diffuse large B-cell lymphoma,DLBCL）最常见的病理亚型,约占所有NHL的20%～25%[1]。我国FL的发病率略低于欧美国家,中国抗癌协会淋巴瘤病理协作组迄今为止的统计数据显示,FL在B细胞NHL中占10%左右。
作者 黄洪晖
机构地区 上海交通大学医学院附属仁济医院血液科
出处 《内科理论与实践》 2011年第1期22-29,共8页 Journal of Internal Medicine Concepts & Practice
基金 上海交通大学医学院附属仁济医院重点学科项目(项目编号:RJ4101306)
关键词 滤泡性淋巴瘤 治疗 利妥昔单抗 放射免疫治疗 造血干细胞移植
分类号 R733.1 [医药卫生—肿瘤]
  • 相关文献

参考文献48

  • 1Heinzelmann F, Ottinger H, Engelhard M, et al. Advanced-stage Ⅲ/Ⅳ follicular lymphoma: treatment strategies for individual patients [J]. Strahlenther Onkol, 2010, 186(5): 247-254.
  • 2Young RC, Longo DL, Glatstein E, et al. The treatment of indolent lymphomas: watchful waiting v aggressive combined modality treatment[J]. Semin Hematol, 1988, 25 (2 Suppl 2): 11-16.
  • 3Brice P, Bastion Y, Lepage E, et al. Comparison in low-tumor-burden follicular lymphomas between an initial notreatment policy, prednimustine, or interferon α: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de 1' Adulte[J]. J Clin Oncol, 1997, 15(3): 1110-1117.
  • 4Ardeshna KM, Smith P, Norton A, et al. Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial[J]. Lancet, 2003,362 (9383): 516-522.
  • 5Salles GA. Clinical features, prognosis and treatment of follicular lymphoma [J]. Hematology Am Soc Hematol Educ Program, 2007, 216-225.
  • 6Dana BW, Dahlberg S, Nathw'ani BN, et al. Long-term follow-up of patients with low-grade malignant lymphomas treated with doxorubicin-based chemotherapy or chemoimmunotherapy[J]. J Clin Oncol, 1993, 11(4): 644- 651.
  • 7l.ister TA, Cullen MH, Beard ME, et at. Comparison of combined and single-agent chemotherapy in non- Hodgkin's lymphoma of favourable histological type[J]. Br Med J, 1978, 1(6112): 533-537.
  • 8Nickenig C. Dreyling M, Hoster E, et al. Combined cyclophosphamide, vincristine, doxombicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity compared with combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle cell lymphomas: results of a prospective randomized trial of the German Low-Grade Lymphoma Study Group[J]. Cancer, 2006, 107(5): 1014-1022.
  • 9Horning SJ. Follicular lymphoma: have we made any progress?[J]. Ann Oncol. 2000. 11 Suppl 1: 23-27.
  • 10Hiddeman W, Kneba M. Dreyling M, et al. Frontline therapy with rituximab added to the combination of cyctophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the Gennan Low-Grade Lymphoma Study Group[J]. Blood, 2005,106( 12): 3725-3732.

同被引文献34

  • 1叶任高.内科学[M]5版[M].北京:人民卫生出版社,2000.961.
  • 2Pregno P, Chiappella A, Bellb M, et al. Interim 18-FDG-PET/CT failed to predict the outcome in diffuse large B-cell lymphoma patients treated at the diagnosis with rituximab-CHOP. Blood, 2012, 119: 2066-2073.
  • 3Kim GE, Koom WS, Yang WI, et al. Clinical relevance of three subtypes of primary sinonasal lymphoma characterized by immunophenotypic analysis. Head Neck, 2004, 26: 584-593.
  • 4Heinzelmann F, Otinger H, Engelhard M, et al. Advanced stage m/Iv follicular lymphoma: treatment stralegies for individual patients. Strahlenther Onkol,201 O, 186: 247-254.
  • 5Haioun C, hti E, Rahmonni A, et al. [18F]fluoro-2-deoxy-D-glucose positron emission tomography(FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome. Blood, 2005, 06: 1376-1381.
  • 6Mikhaecl NG, Hntchings M, Fields PA, et al. FDG-PET after wo to three cycles of chemotherapy predicts progression-free survival and overall survival in high-grade non-Hodgkin lymphoma. Ann Oneol, 2005, 16: 1514-1523.
  • 7Yoo C, Lee DH, Kim JE, et al. Limited role of interim of PET/CT in patients with diffuse large B-cell lymphoma treated with R-CHOP. Ann Hematol, 2011, 90: 797-802.
  • 8Bakhshi S, Radhakrishnan V, Sharma P, et al. Pediatric nonlymphoblasie non-Hodgkin lymphoma: baseline, interim, and posttreatment PET/CT versus eantrast-enhanced CT for evaluation-a prospective study. Radiology, 2012, 262: 956-968.
  • 9Li YJ, Li ZM, Xia XY, et al. Prognostic value of interim and posttherapy 18F-FDG PET/CT in patients with mature T-cell and natural killer cell lymphomas. J Nuel Med, 2013, 54:507-515.
  • 10le Dortz L, De Guibert S, Bayat S, et al. Diagnostic: and prognostic impact of 18F-FDG PET/CT in follicular lymphoma. Eur J Nucl Med Mol Imaging, 2010, 37: 2307-2314.

引证文献3

二级引证文献18

内科理论与实践
2011年 第1期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部